A reliable risk score for stage IV esophagogastric cancer

European Journal of Surgical Oncology

Volumn 39, Issue 8, 2013, Pages 823-830

  Blank, S ^a   Lordick, F ^b   Dobritz, M ^c   Grenacher, L ^d   Burian, M ^a   Langer, R ^c   Roth, W ^a   Schaible, A ^a   Becker, K ^c   Blaker H ^a   Sisic, L ^a   Stange, A ^a   Compani, P ^a   Schulze Bergkamen, H ^a   Jager D ^a   Buchler M ^a   Siewert, J R ^e   Ott, K ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b University Cancer Center Leipzig (UCCL)   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Esophageal cancer; Gastric cancer; Surgery in metastatic disease

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; SCORING SYSTEM; STOMACH CANCER; TREATMENT RESPONSE;

ESOPHAGEAL CANCER; GASTRIC CANCER; SURGERY IN METASTATIC DISEASE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GASTRECTOMY; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; PATIENT SELECTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84879843429     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2013.01.005     Document Type: Article

References (46)

1. C. Schuhmacher, S. Gretschel, and F. Lordick Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954 J Clin Oncol 2010
2. D. Cunningham, W. Allum, and S. Stenning Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med 355 2006 11 20
3. M. Ychou, V. Boige, and J.P. Pignon Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial J Clin Oncol 29 2011 1715 1721
4. S. Lorenzen, M. Hentrich, and C. Haberl Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial Ann Oncol 18 2007 1673 1679
5. S.E. Al-Batran, J.T. Hartmann, and R. Hofheinz Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Ann Oncol 19 2008 1882 1887
6. H.H. Hartgrink, H. Putter, and E. Klein Kranenbarg Value of palliative resection in gastric cancer Br J Surg 89 2002 1438 1443
7. O. Nazli, I. Yaman, and T. Tansuǧ Palliative surgery for advanced stage (stage IV) gastric adenocarcinoma Hepatogastroenterology 54 2007 298 303
8. V. Kahlke, B. Bestmann, and A. Schmid Palliation of metastatic gastric cancer: impact of preoperative symptoms and the type of operation on survival and quality of life World J Surg 28 2004 369 375
9. H. Medina-Franco, A. Contreras-Saldívar, and A. Ramos-De La Medina Surgery for stage IV gastric cancer Am J Surg 187 2004 543 546
10. R.F. Saidi, S.G. ReMine, P.S. Dudrick, and N.N. Hanna Is there a role for palliative gastrectomy in patients with stage IV gastric cancer? World J Surg 30 2006 21 27
11. S. Ishigami, S. Natsugoe, and A. Nakajo Salvage gastrectomy following a combination of biweekly paclitaxel and S-1 for stage IV gastric cancer J Gastrointest Surg 12 2008 1370 1375
12. K. Yamashita, S. Sakuramoto, and S. Kikuchi Surgical resection of stage IV gastric cancer and prognosis Anticancer Res 27 2007 4381 4386
13. J.Y. An, T.K. Ha, J.H. Noh, T.S. Sohn, and S. Kim Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM Arch Surg 144 2009 38 45 [discussion]
14. F. Lordick To resect or not resect in metastatic gastric cancer: that is the question! Gastric Cancer 2012
15. Y. Emi, M. Yamamoto, and I. Takahashi Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer Surg Today 38 2008 1013 1020
16. F.G. Bader, F. Lordick, and U. Fink Paclitaxel in the neoadjuvant treatment for adenocarcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up Onkologie 31 2008 366 372
17. V. Kaechele, M. Moehler, and M.P. Lutz A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie Cancer Chemother Pharmacol 66 2010 191 195
18. M. Nishiyama, and S. Wada Docetaxel: its role in current and future treatments for advanced gastric cancer Gastric Cancer 12 2009 132 141
19. Y.J. Bang, E. Van Cutsem, and A. Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
20. T. Okuyama, D. Korenaga, and K. Koushi The prognostic significance of chemotherapy for stage IV gastric cancer patients: a single-institution experience Surg Today 41 2011 935 940
21. E. Van Cutsem, D. Haller, and A. Ohtsu The role of chemotherapy in the current treatment of gastric cancer Gastric Cancer 5 Suppl. 1 2002 17 22
22. S.E. Al-Batran, E. Jäger, and M. Scholz Chemotherapy for advanced gastric cancer J Clin Oncol 25 2007 729 author reply 30
23. K. Ott, U. Fink, and K. Becker Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial J Clin Oncol 21 2003 4604 4610
24. U. Fink, C. Schuhmacher, and H.J. Stein Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection Br J Surg 82 1995 1248 1252
25. W.A. Weber, K. Ott, and K. Becker Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 2001 3058 3065
26. K. Becker, J. Mueller, and C. Schulmacher Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy Cancer 98 2003 1521 1530
27. C. Mariette, J.M. Balon, and V. Maunoury Value of endoscopic ultrasonography as a predictor of long-term survival in oesophageal carcinoma Br J Surg 90 2003 1367 1372
28. C. Mariette, L. Finzi, and S. Fabre Factors predictive of complete resection of operable esophageal cancer: a prospective study Ann Thorac Surg 75 2003 1720 1726
29. M.B. Mortensen, C.W. Fristrup, and A.P. Ainsworth Combined preoperative endoscopic and laparoscopic ultrasonography for prediction of R0 resection in upper gastrointestinal tract cancer Br J Surg 93 2006 720 725
30. J.B. Hulscher, E.J. Nieveen van Dijkum, and L.T. de Wit Laparoscopy and laparoscopic ultrasonography in staging carcinoma of the gastric cardia Eur J Surg 166 2000 862 865
31. J. Siewert, K. Böttcher, H. Stein, and J. Roder Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study Ann Surg 228 1998 449 461
32. R. Langer, K. Ott, and M. Feith Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas Mod Pathol 22 2009 1555 1563
33. K. Becker, R. Langer, and D. Reim Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases Ann Surg 253 2011 934 939
34. A. Lowy, P. Mansfield, and S. Leach Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer Ann Surg 229 1999 303 308
35. D.P. Kelsen, K.A. Winter, and L.L. Gunderson Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer J Clin Oncol 25 2007 3719 3725
36. K. Ott, A. Sendler, and K. Becker Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study Gastric Cancer 6 2003 159 167
37. S. Schmidt, N. Schlechtweg, and W. Veltzke-Schlieker Clinical and pathological prognostic factors for cancers of the esophagogastric junction Zentralbl Chir 134 2009 455 461
38. Y. Adachi, K. Yasuda, and M. Inomata Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type Cancer 89 2000 1418 1424
39. S. Lorenzen, S. Blank, F. Lordick, J.R. Siewert, and K. Ott Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients Ann Surg Oncol 2012
40. J.Z. Zhang, H.S. Lu, and C.M. Huang Outcome of palliative total gastrectomy for stage IV proximal gastric cancer Am J Surg 202 2011 91 96
41. K. Hanazaki, H. Sodeyama, and Y. Mochizuki Palliative gastrectomy for advanced gastric cancer Hepatogastroenterology 48 2001 285 289
42. S.P. Kerkar, C.D. Kemp, and I. Avital Liver resections in metastatic gastric cancer HPB (Oxford) 12 2010 589 596
43. T. Kanda, K. Yajima, and S.I. Kosugi Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study Gastric Cancer 2011
44. F. Lordick, K. Ott, and B.J. Krause PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet Oncol 8 2007 797 805
45. J.R. Siewert, F. Lordick, and K. Ott Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome Ann Surg 246 2007 624 628 discussion 8-31
46. S.R. Markar, A. Karthikesalingam, and S. Thrumurthy Low DE volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011 J Gastrointest Surg 2011